Literature DB >> 28365900

Invasive listeriosis in a patient with several episodes of antibiotic associated colitis presumably due to Clostridium difficile.

Novella Carannante1, Pasquale Pagliano1, Marco Rossi1, Vittorio Attanasio1, Carolina Rescigno1, Laura Corte2, Carlo Tascini1, Gianluigi Cardinali3,4.   

Abstract

A 62-year-old man developed a blood stream infection and meningitis due to Listeria monocytogenes, 20 days after an episode of pseudo-membranous colitis. The patient, hospitalized for the first time for transurethral prostatectomy, was readmitted 20 days later with watery diarrhea. Pseudo-membranous colitis was diagnosed and treated successfully, without testing for Clostridium difficile infection (CDI). After 15 more days, the patient developed again diarrhea, fever and confusion. Hospitalized again, blood and cerebrospinal fluid cultures resulted positive for L. monocytogenes. The patient was treated successfully and a diagnosis of recurrent CDI was confirmed following culture and nucleic acid amplification assays both positive for C. difficile. This is the first report of an invasive listeriosis after CDI underlines the importance of taking greater awareness in complicated blood stream infections that may arise after CDI.

Entities:  

Keywords:  Blood stream infections; Clostridium difficile; Listeria monocytogenes

Mesh:

Substances:

Year:  2017        PMID: 28365900     DOI: 10.1007/s15010-017-1013-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Clostridium difficile toxin A alters in vitro-adherent neutrophil morphology and function.

Authors:  Gerly A C Brito; Gail W Sullivan; William P Ciesla; Holliday T Carper; Gerald L Mandell; Richard L Guerrant
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

2.  Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection.

Authors:  Marco Falcone; Alessandro Russo; Federica Iraci; Paolo Carfagna; Paola Goldoni; Vincenzo Vullo; Mario Venditti
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

3.  European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).

Authors:  M P Bauer; E J Kuijper; J T van Dissel
Journal:  Clin Microbiol Infect       Date:  2009-12       Impact factor: 8.067

4.  Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Authors:  Cirle A Warren; Edward J van Opstal; Mary S Riggins; Yuesheng Li; John H Moore; Glynis L Kolling; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 5.  Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis.

Authors:  Ioannis M Zacharioudakis; Fainareti N Zervou; Elina Eleftheria Pliakos; Panayiotis D Ziakas; Eleftherios Mylonakis
Journal:  Am J Gastroenterol       Date:  2015-03-03       Impact factor: 10.864

Review 6.  Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature.

Authors:  Simone Meini; Raffaele Laureano; Lucia Fani; Carlo Tascini; Angelo Galano; Alberto Antonelli; Gian Maria Rossolini
Journal:  Infection       Date:  2015-05-30       Impact factor: 3.553

7.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 8.  Clinical recognition and diagnosis of Clostridium difficile infection.

Authors:  John G Bartlett; Dale N Gerding
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

9.  Impact of selected Lactobacillus and Bifidobacterium species on Listeria monocytogenes infection and the mucosal immune response.

Authors:  Sinead C Corr; Cormac G M Gahan; Colin Hill
Journal:  FEMS Immunol Med Microbiol       Date:  2007-05-30

10.  Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.

Authors:  Michelle M Nerandzic; Kathleen Mullane; Mark A Miller; Farah Babakhani; Curtis J Donskey
Journal:  Clin Infect Dis       Date:  2012-08       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.